{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:15:57Z","timestamp":1780406157873,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"University of Nebraska Medical Center Department of Internal Medicine"},{"name":"Division of Cardiovascular Medicine"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pharmthera.2019.107413","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:42:58Z","timestamp":1571168578000},"page":"107413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease"],"prefix":"10.1016","volume":"205","author":[{"given":"Dahn L.","family":"Clemens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Duryee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan H.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynell W.","family":"Klassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation\/CRP evaluation (PRINCE): A randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.pharmthera.2019.107413_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107440","article-title":"Unique antibody responses to malondialdehyde-acetaldehyde (MAA)-protein adducts predict coronary artery disease","volume":"9","author":"Anderson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.freeradbiomed.2015.09.003","article-title":"Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease","volume":"89","author":"Antoniak","year":"2015","journal-title":"Free Radical Biology & Medicine"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2019.107413_bib0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11010-013-1848-7","article-title":"Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR","volume":"386","author":"Antonio","year":"2014","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107413_bib0025","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0030","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/360438","article-title":"Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal","volume":"2014","author":"Ayala","year":"2014","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mva.2002.125018","article-title":"Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: Report of a prospective (Phase II) multicenter study","volume":"36","author":"Baxter","year":"2002","journal-title":"Journal of Vascular Surgery"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.phrs.2011.05.002","article-title":"Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease","volume":"64","author":"Bench","year":"2011","journal-title":"Pharmacological Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107413_bib0045","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke Statistics-2017 update: A report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107413_bib0050","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/nm1102-1218","article-title":"Innate and acquired immunity in atherogenesis","volume":"8","author":"Binder","year":"2002","journal-title":"Nature Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107413_bib0055","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nri.2016.63","article-title":"Innate sensing of oxidation-specific epitopes in health and disease","volume":"16","author":"Binder","year":"2016","journal-title":"Nature Reviews Immunology"},{"issue":"9237","key":"10.1016\/j.pharmthera.2019.107413_bib0060","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmthera.2019.107413_bib0065","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.4049\/jimmunol.177.7.4350","article-title":"Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice","volume":"177","author":"Bracke","year":"2006","journal-title":"Journal of Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0070","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/01.ATV.0000121571.78696.dc","article-title":"Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial","volume":"24","author":"Brown","year":"2004","journal-title":"Arteriosclerosis Thrombosis and Vascular Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbalip.2016.06.016","article-title":"Malondialdehyde epitopes as mediators of sterile inflammation","volume":"1862","author":"Busch","year":"2017","journal-title":"Biochimica et Biophysica Acta"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2011.05.005","article-title":"Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases","volume":"64","author":"Castro","year":"2011","journal-title":"Pharmacological Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0085","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00395-014-0412-2","article-title":"Effects of a timely therapy with doxycycline on the left ventricular remodeling according to the pre-procedural TIMI flow grade in patients with ST-elevation acute myocardial infarction","volume":"109","author":"Cerisano","year":"2014","journal-title":"Basic Research in Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0090","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/eurheartj\/eht420","article-title":"Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial","volume":"35","author":"Cerisano","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0095","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2015.06.024","article-title":"Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial","volume":"197","author":"Cerisano","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107413_bib0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19124078","article-title":"Novel antioxidant properties of doxycycline","volume":"19","author":"Clemens","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0105","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/ncomms15019","article-title":"Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression","volume":"8","author":"Corciulo","year":"2017","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nature Reviews Rheumatology"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107413_bib0115","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.bbagen.2016.06.022","article-title":"Polyphenol compounds and PKC signaling","volume":"1860","author":"Das","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ced.12062","article-title":"Systemic methotrexate therapy for psoriasis: Past, present and future","volume":"38","author":"Dogra","year":"2013","journal-title":"Clinical and Experimental Dermatology"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107413_bib0125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.freeradbiomed.2010.08.001","article-title":"Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis","volume":"49","author":"Duryee","year":"2010","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radical Biology & Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"American Heart Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107413_bib0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"9177","key":"10.1016\/j.pharmthera.2019.107413_bib0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto miocardico","volume":"354","author":"GISSI-Prevention","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0150","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: A pleitropic family of compounds with promising therapeutic properties. Review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"American Journal of Physiology Cell Physiology"},{"issue":"16","key":"10.1016\/j.pharmthera.2019.107413_bib0155","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107413_bib0160","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0021-9150(98)00153-1","article-title":"Association of malondialdehyde-acetaldehyde (MAA) adducted proteins with atherosclerotic-induced vascular inflammatory injury","volume":"141","author":"Hill","year":"1998","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0170","first-page":"4","article-title":"Methotrexate: role of treatment in skin disease","volume":"18","author":"Holliday","year":"2013","journal-title":"Skin Therapy Letter"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0175","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.09.001","article-title":"The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules","volume":"114","author":"Johnston","year":"2005","journal-title":"Clinical Immunology"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107413_bib0180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/BF02534718","article-title":"Studies on peroxidized lipids. V. Formation and characterization of 1,4-dihydropyridine-3,5-dicarbaldehydes as model of fluorescent components in lipofuscin","volume":"19","author":"Kikugawa","year":"1984","journal-title":"Lipids"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0185","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1471-4159.2005.03219.x","article-title":"Antioxidant properties of minocycline: Neuroprotection in an oxidative stress assay and direct radical-scavenging activity","volume":"94","author":"Kraus","year":"2005","journal-title":"Journal of Neurochemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107413_bib0190","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/01.RES.85.8.753","article-title":"Oxidative stress as a regulator of gene expression in the vasculature","volume":"85","author":"Kunsch","year":"1999","journal-title":"Circulation Research"},{"issue":"6917","key":"10.1016\/j.pharmthera.2019.107413_bib0195","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.pharmthera.2019.107413_bib0200","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Inflammation in atherosclerosis: From pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"7347","key":"10.1016\/j.pharmthera.2019.107413_bib0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0210","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0741-5214(03)01022-X","article-title":"Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells","volume":"38","author":"Liu","year":"2003","journal-title":"Journal of Vascular Surgery"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0215","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1582-4934.2009.00897.x","article-title":"Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems","volume":"14","author":"Lu","year":"2010","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0220","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1538-7836.2004.01085.x","article-title":"Oxidative stress in atherogenesis and arterial thrombosis: The disconnect between cellular studies and clinical outcomes","volume":"3","author":"Madamanchi","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.ATV.0000150649.39934.13","article-title":"Oxidative stress and vascular disease","volume":"25","author":"Madamanchi","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0230","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/714653","article-title":"The role of oxidized low-density lipoproteins in atherosclerosis: The myths and the facts","volume":"2013","author":"Maiolino","year":"2013","journal-title":"Mediators of Inflammation"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107413_bib0235","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.bbagen.2012.10.018","article-title":"Mitochondrial glutathione: Features, regulation and role in disease","volume":"1830","author":"Mari","year":"2013","journal-title":"Biochimica et Biophysica Acta"},{"issue":"22","key":"10.1016\/j.pharmthera.2019.107413_bib0240","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa1608889","article-title":"Trial of minocycline in a clinically isolated syndrome of multiple sclerosis","volume":"376","author":"Metz","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2019.107413_bib0245","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"The American Journal of Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.tem.2016.11.002","article-title":"Context-dependent role of oxidized lipids and lipoproteins in inflammation","volume":"28","author":"Miller","year":"2017","journal-title":"Trends in Endocrinology and Metabolism: TEM"},{"issue":"7","key":"10.1016\/j.pharmthera.2019.107413_bib0255","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxidants & Redox Signaling"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107413_bib0260","first-page":"631","article-title":"Oxidative stress and human hypertension: Vascular mechanisms, biomarkers, and novel therapies","volume":"31","author":"Montezano","year":"2015","journal-title":"The Canadian Journal of Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0265","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/art.21620","article-title":"Treatment of early seropositive rheumatoid arthritis: Doxycycline plus methotrexate versus methotrexate alone","volume":"54","author":"O\u2019Dell","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0270","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1073\/pnas.86.4.1372","article-title":"Low density lipoprotein undergoes oxidative modification in vivo","volume":"86","author":"Palinski","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"18","key":"10.1016\/j.pharmthera.2019.107413_bib0275","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1021\/acs.chemrev.7b00698","article-title":"Redox signaling by reactive electrophiles and oxidants","volume":"118","author":"Parvez","year":"2018","journal-title":"Chemical Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107413_bib0280","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/rheumatology\/23.2.92","article-title":"Cause of death in rheumatoid arthritis","volume":"23","author":"Prior","year":"1984","journal-title":"British Journal of Rheumatology"},{"issue":"21","key":"10.1016\/j.pharmthera.2019.107413_bib0285","doi-asserted-by":"crossref","first-page":"13481","DOI":"10.1073\/pnas.172501499","article-title":"Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics","volume":"99","author":"Rajagopalan","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107413_bib0290","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0295","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: Targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circulation Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.pharmthera.2019.107413_bib0305","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0310","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","author":"Ridker","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107413_bib0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.dsx.2017.12.029","article-title":"Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of cardiovascular disease risk","volume":"12","author":"Robson","year":"2018","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0330","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"13","key":"10.1016\/j.pharmthera.2019.107413_bib0335","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.2174\/1389201011208062456","article-title":"Novel therapeutic approaches in limiting oxidative stress and inflammation","volume":"13","author":"Spychalowicz","year":"2012","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0340","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/1099800409346333","article-title":"The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds","volume":"11","author":"Stechmiller","year":"2010","journal-title":"Biological Research for Nursing"},{"issue":"17","key":"10.1016\/j.pharmthera.2019.107413_bib0345","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1161\/01.CIR.0000014762.06201.06","article-title":"Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?","volume":"105","author":"Steinberg","year":"2002","journal-title":"Circulation"},{"issue":"9004","key":"10.1016\/j.pharmthera.2019.107413_bib0350","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(96)90866-1","article-title":"Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)","volume":"347","author":"Stephens","year":"1996","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107413_bib0355","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/j.1530-0277.1998.tb03973.x","article-title":"Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant","volume":"22","author":"Thiele","year":"1998","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0360","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1749-6632.1999.tb07682.x","article-title":"MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial","volume":"878","author":"Thompson","year":"1999","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ab.2016.10.021","article-title":"Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges","volume":"524","author":"Tsikas","year":"2017","journal-title":"Analytical Biochemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107413_bib0370","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1530-0277.1987.tb00178.x","article-title":"Covalent binding of acetaldehyde to proteins: Participation of lysine residues","volume":"11","author":"Tuma","year":"1987","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"7121","key":"10.1016\/j.pharmthera.2019.107413_bib0375","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.pharmthera.2019.107413_bib0380","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.288.19.2432","article-title":"Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial","volume":"288","author":"Waters","year":"2002","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.pharmthera.2019.107413_bib0385","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0390","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1377\/hlthaff.26.1.25","article-title":"Advances in the prevention and treatment of cardiovascular disease","volume":"26","author":"Weisfeldt","year":"2007","journal-title":"Health Affairs (Millwood)"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107413_bib0395","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","article-title":"Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis","volume":"47","author":"Wessels","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107413_bib0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1530-0277.2002.tb02436.x","article-title":"In vitro exposure to malondialdehyde-acetaldehyde adducted protein inhibits cell proliferatin and viability","volume":"26","author":"Willis","year":"2002","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"10\u201311","key":"10.1016\/j.pharmthera.2019.107413_bib0405","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S1567-5769(03)00136-X","article-title":"T cell proliferative responses to malondialdehyde-acetaldehyde haptenated protein are scavenger receptor mediated","volume":"3","author":"Willis","year":"2003","journal-title":"International Immunopharmacology"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2019.107413_bib0410","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1050-1738(01)00111-6","article-title":"The oxidative modification hypothesis of atherosclerosis: does it hold for humans?","volume":"11","author":"Witztum","year":"2001","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107413_bib0415","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1172\/JCI114271","article-title":"Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man","volume":"84","author":"Yla-Herttuala","year":"1989","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2019.107413_bib0420","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.redox.2017.07.018","article-title":"Direct antioxidant properties of methotrexate: Inhibition of malondialdehyde-acetaldehyde-protein adduct formation and superoxide scavenging","volume":"13","author":"Zimmerman","year":"2017","journal-title":"Redox Biology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:03:30Z","timestamp":1759010610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":84,"alternative-id":["S0163725819301652"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107413","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevance of the antioxidant properties of methotrexate and doxycycline to their treatment of cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107413"}}